Science & Technology
Novel Therapy for Hyperphosphatemic Familial Tumoral Calcinosis (hfTC) and Generalized Hyperphosphatemia
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R41AR084025-01
Award Ceiling
$302K
Award Floor
$302K
Close Date
Aug 31, 2024
Total Funding
$302K
Expected Awards
1
Posted Date
Sep 19, 2023
Cost Sharing Required
No
Grants.gov ID
sbir-1R41AR084025-01
Description
STTR Phase Phase I award: "Novel Therapy for Hyperphosphatemic Familial Tumoral Calcinosis (hfTC) and Generalized Hyperphosphatemia" awarded to FGF Therapeutics INC. in Zionsville, Indiana. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $301,892. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.